Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates.
Nakamura R, Auayporn N, Smith DD, Palmer J, Sun JY, Schriber J, Pullarkat V, Parker P, Rodriguez R, Stein A, Rosenthal J, Wang S, Karanas C, Gaal K, Senitzer D, Forman SJ. Nakamura R, et al. Among authors: senitzer d. Biol Blood Marrow Transplant. 2008 Apr;14(4):449-57. doi: 10.1016/j.bbmt.2008.02.005. Biol Blood Marrow Transplant. 2008. PMID: 18342788 Free PMC article.
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.
Stein AS, Palmer JM, O'Donnell MR, Kogut NM, Spielberger RT, Slovak ML, Tsai NC, Senitzer D, Snyder DS, Thomas SH, Forman SJ. Stein AS, et al. Among authors: senitzer d. Biol Blood Marrow Transplant. 2009 Nov;15(11):1407-14. doi: 10.1016/j.bbmt.2009.07.003. Biol Blood Marrow Transplant. 2009. PMID: 19822300 Free PMC article.
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A, Snyder D, Pullarkat V, Kogut N, Rosenthal J, Smith E, Karanes C, O'Donnell M, Krishnan AY, Senitzer D, Forman SJ. Rodriguez R, et al. Among authors: senitzer d. Blood. 2010 Feb 4;115(5):1098-105. doi: 10.1182/blood-2009-03-207563. Epub 2009 Nov 19. Blood. 2010. PMID: 19965688 Free PMC article. Clinical Trial.
Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis.
Nakamura R, Palmer JM, O'Donnell MR, Stiller T, Thomas SH, Chao J, Alvarnas J, Parker PM, Pullarkat V, Maegawa R, Stein AS, Snyder DS, Bhatia R, Chang K, Wang S, Cai JL, Senitzer D, Forman SJ. Nakamura R, et al. Among authors: senitzer d. Leuk Res. 2012 Sep;36(9):1152-6. doi: 10.1016/j.leukres.2012.04.022. Epub 2012 Jun 5. Leuk Res. 2012. PMID: 22677229 Free PMC article.
Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms' tumor antigen in patients with non-Hodgkin lymphoma.
Israyelyan A, La Rosa C, Tsai W, Kaltcheva T, Srivastava T, Aquino L, Li J, Kim Y, Palmer J, Streja L, Senitzer D, Zaia JA, Rosenwald A, Forman SJ, Nakamura R, Diamond DJ. Israyelyan A, et al. Among authors: senitzer d. Leuk Lymphoma. 2013 Nov;54(11):2490-9. doi: 10.3109/10428194.2013.783910. Epub 2013 Apr 30. Leuk Lymphoma. 2013. PMID: 23480492 Free PMC article.
Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
Khaled SK, Palmer JM, Herzog J, Stiller T, Tsai NC, Senitzer D, Liu X, Thomas SH, Shayani S, Weitzel J, Forman SJ, Nakamura R. Khaled SK, et al. Among authors: senitzer d. Biol Blood Marrow Transplant. 2016 Feb;22(2):268-276. doi: 10.1016/j.bbmt.2015.08.027. Epub 2015 Aug 30. Biol Blood Marrow Transplant. 2016. PMID: 26325438 Free PMC article.
Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation.
Nakamura R, Gendzekhadze K, Palmer J, Tsai NC, Mokhtari S, Forman SJ, Zaia JA, Senitzer D, Marcucci G, Stein A. Nakamura R, et al. Among authors: senitzer d. Leuk Res. 2019 Dec;87:106230. doi: 10.1016/j.leukres.2019.106230. Epub 2019 Sep 28. Leuk Res. 2019. PMID: 31644966 Free PMC article.
A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant.
Khaled SK, Palmer J, Stiller T, Senitzer D, Maegawa R, Rodriguez R, Parker PM, Nademanee A, Cai JL, Snyder DS, Karanes C, Osorio E, Thomas SH, Forman SJ, Nakamura R. Khaled SK, et al. Among authors: senitzer d. Bone Marrow Transplant. 2013 Feb;48(2):278-83. doi: 10.1038/bmt.2012.175. Epub 2012 Sep 24. Bone Marrow Transplant. 2013. PMID: 23000644 Free PMC article. Clinical Trial.
Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.
Fung HC, Cohen S, Rodriguez R, Smith D, Krishnan A, Somlo G, Sahebi F, Senitzer D, O'Donnell MR, Stein A, Snyder DS, Spielberger R, Bhatia R, Falk P, Molina A, Nademanee A, Parker P, Kogut N, Popplewell L, Vora N, Margolin K, Forman SJ. Fung HC, et al. Among authors: senitzer d. Biol Blood Marrow Transplant. 2003 Oct;9(10):649-56. doi: 10.1016/s1083-8791(03)00241-6. Biol Blood Marrow Transplant. 2003. PMID: 14569561 Free article. Clinical Trial.
105 results